What Are Incretins and How Do They Work?

Incretins are gut hormones released after you eat that amplify your body’s insulin response to food. The two main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and together they account for roughly half of the insulin your pancreas secretes after a meal.¹ That outsized role in blood-sugar management is why incretin-based drugs have become some of the most prescribed medications in the world, but the story of what these hormones actually do reaches far beyond the pancreas.

How Scientists Discovered the Incretin Effect

Even before insulin was formally identified, researchers noticed something odd: sugar taken by mouth provoked a much stronger insulin response than the same amount of sugar delivered directly into a vein. That gap, the extra insulin kick triggered by eating rather than bypassing the gut, became known as the “incretin effect.”² It took decades to pin down which molecules were responsible. GIP was isolated first, from porcine intestine, initially because it could dampen stomach-acid secretion; only later did researchers realize it also stimulated insulin release.³ GLP-1 came next, identified in the 1980s from cells lining the lower intestine. Together, these two hormones explained the mystery: eating triggers a hormonal relay from gut to pancreas that intravenous glucose simply skips.

GLP-1 and GIP, Side by Side

Although GLP-1 and GIP both boost insulin, they are produced by different cells in different parts of the intestine and have some distinct roles. GIP is a 42-amino-acid hormone secreted by K cells concentrated in the upper small intestine, released quickly once nutrients hit that stretch of the gut.³ GLP-1 comes from L cells found mainly in the lower small intestine and colon. Both hormones share a crucial safety feature: they stimulate insulin secretion only when blood sugar is already elevated. That glucose-dependent behavior means they do not push blood sugar dangerously low under normal conditions, which is a meaningful advantage over older diabetes drugs that can cause hypoglycemia regardless of what your blood sugar is doing.

GLP-1 does more than nudge insulin upward. It also suppresses glucagon, the hormone that tells your liver to dump stored sugar into the bloodstream. It slows gastric emptying, keeping food in your stomach longer so sugar enters the bloodstream more gradually. And it acts on the brain to promote satiety, the feeling that you have eaten enough.⁴ GIP, by contrast, has a weaker track record on appetite suppression, and its effects on glucagon are more complex and context-dependent. These differences explain why drug development has historically leaned more heavily on GLP-1 as a therapeutic target.

Why Incretins Barely Last Minutes in Your Body

One of the frustrating things about natural GLP-1 and GIP is how quickly your body destroys them. An enzyme called dipeptidyl peptidase-4, or DPP-4, chops both hormones apart within a few minutes of their release.⁵ DPP-4 is everywhere in the body, on blood vessel walls, the surface of immune cells, in the kidneys. That rapid degradation means natural GLP-1 has a half-life measured in minutes, not hours. Your body produces it in small pulses timed to meals, and each pulse is quickly cleaned up.

This short lifespan created two parallel strategies for incretin-based drugs. One approach blocks DPP-4 so that your own natural incretins stick around longer. These are the DPP-4 inhibitors, sometimes called gliptins, and they produce a modest but real boost in incretin levels. The other approach sidesteps the problem entirely by engineering GLP-1-like molecules that DPP-4 cannot easily break down. These are the GLP-1 receptor agonists, and their impact on blood sugar and body weight is substantially larger.

From Gila Monster Venom to Weekly Injections

The first GLP-1 receptor agonist came from an unlikely source. Researchers studying the venom of the Gila monster, a venomous lizard native to the American Southwest, isolated a peptide called exendin-4 that shared about half its structure with human GLP-1 but resisted DPP-4 breakdown far more effectively.⁶ That peptide became exenatide, marketed as Byetta in 2005 and given as a twice-daily injection. It was a proof of concept that mimicking GLP-1 could work as a drug, but the injection schedule was inconvenient.

Later drugs like liraglutide and semaglutide took a different engineering approach. Instead of borrowing a lizard peptide, they modified human GLP-1 itself by attaching fatty acid chains that let the molecule latch onto albumin, a large and abundant protein in the blood. The albumin acts as a kind of protective shuttle, shielding the drug from DPP-4 and slowing its clearance through the kidneys.⁷ Liraglutide can be injected once daily; semaglutide once weekly. That progression from twice-daily lizard venom derivative to once-weekly modified human peptide reflects how well scientists have learned to extend incretin half-life.

What Happens to the Incretin Effect in Type 2 Diabetes

In people without diabetes, the incretin effect is responsible for roughly half of the insulin secreted after eating. In people with type 2 diabetes, that contribution drops to about 30 percent or less.¹ The hormones themselves may still be released in fairly normal amounts, but the pancreatic beta cells become less responsive to them, a phenomenon sometimes called incretin resistance. Chronic high blood sugar, ongoing inflammation, and genetic factors all appear to impair signaling through the GLP-1 and GIP receptors on those cells, creating a vicious cycle: poor incretin signaling worsens blood sugar control, and poor blood sugar control further degrades incretin signaling.

This is why pharmacological doses of GLP-1 receptor agonists work even though the patient’s own incretins are underperforming. The drug concentrations achieved by injection are many times higher than what the gut naturally produces, enough to overcome that resistance and drive meaningful insulin secretion. It also explains why GLP-1 receptor agonists tend to be more effective than DPP-4 inhibitors: the gliptins merely preserve the patient’s own (already diminished) incretin output, while the agonists flood the system with a far larger signal.

How Incretins Talk to the Brain

GLP-1 receptors are not just on the pancreas. They are scattered across multiple brain regions involved in appetite, reward, and autonomic control. In the hypothalamus, GLP-1 receptor activation influences satiation, the feeling that tells you to stop eating mid-meal. The dorsomedial hypothalamus appears to be a key target for GLP-1 receptor agonists, mediating what researchers describe as “pre-ingestive cognitive satiation,” essentially changing how much food you want before you even start feeling physically full.⁴ Injecting GLP-1 or its mimics into nearly any brain region that expresses the receptor produces some degree of appetite suppression.⁸

These brain effects have turned GLP-1 receptor agonists into blockbuster weight-loss drugs, not just diabetes treatments. The slowed gastric emptying and peripheral satiety signals are part of the story, but the direct rewiring of central appetite circuits seems to be at least equally important. Patients on semaglutide often describe a quieting of “food noise,” a reduction in intrusive thoughts about eating, which maps well onto the brain-level effects researchers observe in animal studies.

Incretins and the Reward System

GLP-1 receptors also show up in brain areas tied to reward and motivation, including the ventral tegmental area, the nucleus accumbens, and the prefrontal cortex. These regions are heavily implicated in addiction, and activating GLP-1 receptors there modulates dopamine and glutamate signaling in ways that reduce the reinforcing effects of various substances.⁹ In animal studies, GLP-1 receptor agonists reduce the self-administration of alcohol, nicotine, cocaine, and amphetamines, and they dampen relapse-like behavior after a period of abstinence.¹⁰

This is still early-stage research, and animal models of addiction do not always translate cleanly to humans. But anecdotal reports from patients on semaglutide or tirzepatide describing reduced cravings for alcohol, sugary foods, or nicotine are consistent with the preclinical data. Clinical trials specifically testing GLP-1 receptor agonists for alcohol use disorder and smoking cessation are underway. If those results hold up, incretin-based drugs could end up with a therapeutic footprint much broader than anyone anticipated when they were first designed for blood sugar control.

Heart, Kidney, and Liver Effects

Large cardiovascular outcome trials of GLP-1 receptor agonists have consistently shown reductions in major cardiac events in people with type 2 diabetes, which is part of why these drugs moved so rapidly into mainstream prescribing. The proposed mechanisms are not fully settled but involve several overlapping pathways: blood pressure reduction, weight loss, improved glucose control, and decreased oxidative stress.¹¹ Similar protective signals have emerged for kidney function, with these drugs slowing the progression of diabetic kidney disease in trials.

The liver story is particularly striking. Metabolic-associated steatotic liver disease (formerly called nonalcoholic fatty liver disease) affects a large fraction of people with obesity and diabetes, and until recently there were almost no effective drug treatments. A meta-analysis of clinical trials found that GLP-1 receptor agonists tripled the likelihood of resolving the inflammatory form of the disease without worsening scarring, and also improved fibrosis itself.¹² That kind of effect size is unusual in liver disease, and it has made GLP-1 receptor agonists a leading contender for treating a condition that currently lacks good pharmacological options.

The Neuroprotection Question

GLP-1 receptors are expressed throughout the brain, and preclinical studies in animal models of Alzheimer’s and Parkinson’s disease have found a long list of protective effects from activating them: reduced amyloid and tau pathology, lower neuroinflammation, improved mitochondrial function, protection of synapses, and even signs of new nerve cell growth.¹³ Drugs like exenatide, lixisenatide, and liraglutide have shown what researchers cautiously call “disease-modifying potential” in early-stage clinical trials for these conditions.¹⁴

The evidence is strongest in Alzheimer’s and Parkinson’s, where there are at least signals of target engagement in humans, meaning the drugs seem to be interacting with the pathways they are supposed to interact with in the brain.¹⁵ For rarer neurodegenerative disorders like ALS, Huntington’s, or multiple sclerosis, the data remain thin. This is an area where the gap between exciting animal data and proven human benefit is still wide, but the sheer number of ongoing trials reflects how seriously the field takes the possibility.

Dual and Triple Agonists

Since GLP-1 and GIP both contribute to the incretin effect, researchers asked whether activating both receptors at once might produce better results than GLP-1 alone. Tirzepatide, the dual GLP-1/GIP receptor agonist, answered that question emphatically. It has shown greater weight loss and glucose-lowering potency than conventional GLP-1 receptor agonists used solo.¹⁶ The exact reasons are still debated, since GIP’s role in weight regulation is complicated and at times seems to work against the effects you would predict from its role in insulin secretion. But the clinical results speak clearly.

The frontier beyond tirzepatide is triple agonism: molecules that activate the GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activity sounds counterintuitive, since glucagon raises blood sugar, but glucagon also increases energy expenditure and promotes fat burning in the liver. Early data suggest that triple agonists may offer even greater weight loss than dual agonists. The leading candidate, retatrutide, has shown promising results in clinical trials, though it has not yet reached the market. Each step up in receptor complexity adds therapeutic power but also adds unpredictability around side effects and long-term safety.

Body Composition and the Muscle-Loss Concern

One of the most frequently raised concerns about incretin-based weight-loss drugs is muscle loss. Any time you lose weight quickly, whether through dieting, surgery, or medication, some of that weight comes from lean tissue rather than fat. In the STEP 1 trial of semaglutide, roughly 30 percent of the weight lost was lean tissue, with fat loss making up the majority. Tirzepatide trials showed similar proportions, around three-quarters fat and one-quarter lean mass, which is in line with what happens during conventional diet-induced weight loss.¹⁷

A real-world study using connected body-composition scales found that GLP-1 receptor agonist users lost a median of about 10 percent of their body weight, broken down as roughly 7.5 percent fat mass loss and 2.3 percent muscle mass loss.¹⁸ The proportions are not alarming by the standards of any weight-loss intervention, but for older adults or people who were already sarcopenic, even a small absolute loss of muscle can matter. Resistance training and adequate protein intake are the standard recommendations to mitigate this, and there is concern that off-label use by people who do not need to lose much weight could produce muscle loss that outweighs any benefit.¹⁹

Why Bariatric Surgery Boosts Incretins

Incretins help explain some of the dramatic metabolic improvements seen after bariatric surgery, particularly procedures like Roux-en-Y gastric bypass and sleeve gastrectomy. After these surgeries, food reaches the lower small intestine faster and in a less digested state, which triggers a much sharper spike in GLP-1 release than normal anatomy would produce.²⁰ One randomized trial measured postprandial GLP-1 concentrations after Roux-en-Y and found they increased by roughly 330 percent at six months, remaining elevated at twelve months.²¹ That massive surge in natural incretin output likely contributes to the rapid improvements in blood sugar control that often appear within days of surgery, well before significant weight has been lost.

Your Gut Bacteria Can Influence Incretin Release

The composition of your gut microbiome affects how much GLP-1 your intestinal L cells produce. When gut bacteria ferment dietary fiber, they generate short-chain fatty acids like acetate, propionate, and butyrate. These molecules stimulate GLP-1 secretion by activating specific receptors on L cells. Mice engineered to lack those receptors show reduced GLP-1 release and impaired glucose tolerance.²² This connection offers one mechanistic explanation for why high-fiber diets tend to improve blood sugar regulation: the fiber feeds bacteria that produce metabolites that in turn amplify your incretin response. It also suggests that the gut microbiome is not just a passive bystander in metabolic health but an active participant in the hormonal signaling that controls blood sugar after meals.

The Push Toward Incretin Pills

Current GLP-1 receptor agonists are peptides, which means they are fragile molecules that the stomach would destroy if swallowed in a standard tablet. Oral semaglutide exists but uses a special absorption enhancer and must be taken on an empty stomach with minimal water, a finicky regimen that limits how much drug actually reaches the bloodstream. The next frontier is small-molecule GLP-1 receptor agonists: entirely non-peptide drugs that activate the same receptor but can be manufactured as conventional pills with more straightforward dosing.²³ These compounds address several practical barriers at once: they could be taken with food, they are cheaper to manufacture than peptide drugs, and they would spare patients the injections that remain a dealbreaker for some.²⁴

Several candidates are in clinical development, and the pharmacology is challenging: the GLP-1 receptor evolved to recognize a peptide, so getting a small molecule to fit into the same binding pocket with enough potency is a non-trivial chemical problem. But the commercial and public-health incentive is enormous. Modeling studies have found that while semaglutide and tirzepatide produce long-term health improvements and reduce downstream medical costs, the high price of the drugs currently offsets those savings.²⁵ Oral small molecules, if they match the efficacy of injectable peptides, could fundamentally change the cost equation and make incretin-based therapy accessible to a much larger population.

1
PubMed Central. The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM)
2
PubMed Central. The Role of Incretins on Insulin Function and Glucose Homeostasis
3
PubMed Central. GIP and GLP‐1, the two incretin hormones: Similarities and differences
4
PubMed Central. Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
5
PubMed Central. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
6
Toxicon. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
7
PubMed Central. The Discovery and Development of Liraglutide and Semaglutide
8
Endocrinology. GLP-1 and the Neurobiology of Eating Control: Recent Advances
9
PubMed Central. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights
10
PubMed Central. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
11
PubMed Central. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
12
PubMed Central. The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
13
PubMed Central. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
14
PubMed Central. GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
15
JCI Insight. The promise of GLP-1 receptor agonists for neurodegenerative diseases
16
PubMed. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
17
PubMed Central. Muscle loss and GLP-1R agonists use
18
PubMed Central. Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data
19
Pharmacological Research. Glucagon-like peptide-1 receptor agonists and muscle mass effects
20
PubMed Central. The Role of GLP-1 in the Metabolic Success of Bariatric Surgery
21
PubMed Central. Greater early postprandial GLP-1 increase after Roux-en-Y than one-anastomosis gastric bypass, with unchanged secretin: a randomized controlled trial
22
PubMed Central. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2
23
PubMed Central. Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
24
Scientia Pharmaceutica. Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
25
JAMA Health Forum. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults